...
首页> 外文期刊>Journal of psychiatric research >The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression.
【24h】

The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression.

机译:参考脑电图(rEEG)在协助选择药物治疗抑郁症中的用途。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To evaluate the efficacy of rEEG((R))-guided pharmacotherapy for the treatment of depression in those circumstances where rEEG and STAR*D provided different recommendations. MATERIALS AND METHODS: This was a randomized, single-blind, parallel group, 12 center, US study of rEEG-guided pharmacotherapy vs. the most effective treatment regimens reported in the NIH sponsored STAR*D study. Relatively treatment-resistant subjects >/=18 years who failed one or more antidepressants were required to have a QIDS-16-SR score >/=13 and a MADRS score >/=26 at baseline. All subjects underwent a washout of all current medications (with some protocol-specified exceptions) for at least five half-lives before receiving a QEEG and rEEG report. Subjects randomized to rEEG were assigned a regimen based on the rEEG report. Control subjects who had failed only SSRI's in their current episode were randomized to receive venlafaxine XR. Control subjects who had failed antidepressants from >/=2 classes of antidepressants were randomized to receive a regimen from Steps 2-4 of the STAR*D study. Treatment lasted 12 weeks. The primary outcome measures were change from baseline for self-rated QIDS-SR16 and Q-LES-Q-SF. RESULTS: A total of 114 subjects were randomized and 89 subjects were evaluable. rEEG-guided pharmacotherapy exhibited significantly greater improvement for both primary endpoints, QIDS-SR16 (-6.8 vs. -4.5, p<0.0002) and Q-LES-Q-SF (18.0 vs. 8.9, p<0.0002) compared to control, respectively, as well as statistical superiority in 9 out of 12 secondary endpoints. CONCLUSIONS: These results warrant additional studies to determine the role of rEEG-guided psychopharmacology in the treatment of depression. If these results were confirmed, rEEG-guided pharmacotherapy would represent an easy, relatively inexpensive, predictive, objective office procedure that builds upon clinical judgment to guide antidepressant medication choice.
机译:目的:在rEEG和STAR * D提供不同建议的情况下,评估以rEEG(R)指导的药物治疗抑郁症的疗效。材料与方法:这是一项随机,单盲,平行研究组,在美国12个中心进行的rEEG指导的药物治疗与NIH赞助的STAR * D研究中报告的最有效的治疗方案进行比较。一种或多种抗抑郁药治疗失败的相对抗药性≥18岁的受试者,其基线时的QIDS-16-SR得分≥13,MADRS得分≥26。在接受QEEG和rEEG报告之前,所有受试者均接受了至少5个半衰期的所有当前药物的冲洗(有一些协议规定的例外)。根据rEEG报告为随机分配给rEEG的受试者分配方案。在当前发作中仅使SSRI失败的对照组被随机分配接受文拉法辛XR治疗。从> / = 2类抗抑郁药中获得抗抑郁药治疗失败的对照受试者被随机分配接受STAR * D研究第2-4步中的治疗方案。治疗持续了12周。主要结局指标是自评估QIDS-SR16和Q-LES-Q-SF的基线变化。结果:总共114名受试者被随机分组​​,并且89名受试者是可评估的。与对照相比,rEEG指导的药物治疗对QIDS-SR16(-6.8 vs.-4.5,p <0.0002)和Q-LES-Q-SF(18.0 vs. 8.9,p <0.0002)的两个主要终点均显示出显着更大的改善,以及12个次要终点指标中9个指标的统计学优势。结论:这些结果值得进行进一步的研究以确定rEEG指导的心理药理学在抑郁症治疗中的作用。如果这些结果得到证实,那么以rEEG为指导的药物治疗将代表一种简单,相对便宜,可预测,客观的办公室程序,该程序基于临床判断指导抗抑郁药物的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号